NYSE Arca · MYO
Myomo Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for MYO: Nov 9, 2026
Myomo Inc. Common Stock is estimated to report earnings on 11/09/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.08. The reported EPS for the same quarter last year was $-0.09.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.08 | $-0.08 | $-0.08 | 2 |
| Dec 2026 | $-0.08 | $-0.07 | $-0.08 | 2 |
| Mar 2027 | $-0.08 | $-0.07 | $-0.08 | 2 |
| Jun 2027 | $-0.06 | $-0.06 | $-0.07 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks · Fintel- RTTNews · Aug 6, 10:30 PM EDTTop Biotech Gainers: CELZ Soars On Patent News, BRVE Debuts Strong, IOVA Revenue Climbs 66%(RTTNews) – Today's top gainers in the biotech space include Creative Medical, boosted by a new U.S. patent covering exosome-based immunotherapy for Type 1 diabetes; Braveheart, following its IPO; Iovance, after reporting a 66% increase in second-quarter revenue; and Sight Scienc
- Zacks · Aug 5, 8:35 PM EDTMyomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue EstimatesMyomo (MYO) delivered earnings and revenue surprises of +30.00% and +14.75%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Jun 15, 10:31 PM EDTTop Biotech Gainers: RGNT Withdraws F-1 Filing, FDA Clears CUPR's Maggot Therapy, MYO On Watch(RTTNews) – Today's top gainers include Regentis, amid developments including its withdrawal of a planned U.S. listing application (Form F-1) with the SEC; Cuprina, following FDA clearance for its maggot debridement therapy; and Intellia, after reporting additional positive resul
- RTTNews · Jun 10, 11:03 PM EDTTop Biotech Gainers: PBLS Soars Over 50%, CLOV Rallies On Legal Win, RNAZ, TMCI On Watch(RTTNews) – Today's top biotech gainers include Parabilis, following a strong debut on its first day of trading; Shoulder Innovations, which recently issued a rosy outlook for the year; and Clover Health, which won a legal victory in its dispute with the U.S. Department of Health
- Zacks · May 28, 8:55 AM EDTMyomo (MYO) Shows Fast-paced Momentum But Is Still a Bargain StockMyomo (MYO) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
- Zacks · May 12, 8:55 AM EDTHere Is Why Bargain Hunters Would Love Fast-paced Mover Myomo (MYO)Myomo (MYO) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
- Zacks · May 7, 7:05 PM EDTMyomo, Inc. (MYO) Reports Q1 Loss, Beats Revenue EstimatesMyomo (MYO) delivered earnings and revenue surprises of +21.74% and +8.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Fintel · Mar 27, 10:16 AM EDTMyomo (MYO) Price Target Decreased by 13.60% to 4.41The average one-year price target for Myomo (NYSEAM:MYO) has been revised to $4.41 / share. This is a decrease of 13.60% from the prior estimate of $5.10 dated February 21, 2026. The price target is an average of many targets provided by analysts. The latest t
- Zacks · Mar 9, 5:35 PM EDTMyomo, Inc. (MYO) Reports Q4 Loss, Tops Revenue EstimatesMyomo (MYO) delivered earnings and revenue surprises of +5.88% and +11.86%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Mar 5, 10:15 PM ESTCresco Labs Inc. (CRLBF) Reports Q4 Loss, Beats Revenue EstimatesCresco Labs Inc. (CRLBF) delivered earnings and revenue surprises of +14.16% and +0.26%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Nov 10, 5:35 PM ESTMyomo, Inc. (MYO) Reports Q3 Loss, Tops Revenue EstimatesMyomo (MYO) delivered earnings and revenue surprises of +18.18% and +8.74%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Nov 6, 7:20 AM ESTPrestige Consumer Healthcare (PBH) Beats Q2 Earnings and Revenue EstimatesPrestige Consumer Healthcare (PBH) delivered earnings and revenue surprises of +10.31% and +6.87%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Myomo Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.